You are here:
standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate
Advice
Following a resubmission.
Standardised allergen extract of grass pollen 75,000 SQ-T per oral lyophilisate (Grazax®) is not recommended for use within NHS Scotland for the treatment of grass pollen induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen.
Although modest clinical benefit has been shown, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Drug Details
| Drug Name: | standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral lyophilisate |
|---|---|
| SMC Drug ID: | 367/07 |
| Manufacturer: | ALK-Abello Ltd |
| Indication: | Grass pollen induced rhinitis and conjunctivitis in adult patients |
| BNF Category: | |
| Sub Category: | 3.4 Antihistamines*** hyposensitisation*** and allergic emergencies |
| Submission Type: | Resubmission |
| Status: | Not Recommended |
| Date Advice Published: | 14 January 2008 |
Archived Advice
| standardised allergen extract of grass pollen from Timothy (Phleum pratense) 75,000 SQ-T per oral ly | Full submission | 7 May 2007 |